🏅 FDA Orphan Designation

Ngenla

somatrogon-ghla

Manufacturer: Pfizer Ireland Pharmaceuticals

Indicated for:

Non-acquired isolated growth hormone deficiencyOrphanRare disorder due to inadequate sharing of the placenta

FDA-Approved Indications (2)

Non-acquired isolated growth hormone deficiencyOrphan Designation

treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone

Rare disorder due to inadequate sharing of the placenta

NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone

Population: pediatric ≥3 years

Indications & Usage

1 INDICATIONS AND USAGE NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone. NGENLA is a human growth hormone analog indicated for treatment of pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone ( 1 ).

💙 Support Programs

View all →

Ngenla

Pfizer Ireland Pharmaceuticals

Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.